

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – February 14, 2018 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. December 13, 2017 DUR Minutes – Vote

B. December 13, 2017 DUR Recommendations Memorandum

C. January 10, 2018 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – See Appendix B

A. Medication Coverage Activity for January 2018

B. Pharmacy Help Desk Activity for January 2018

C. Chronic Medication Adherence Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Zerviate™ (Cetirizine Ophthalmic Solution) – See Appendix C

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize ArmonAir™ RespiClick® (Fluticasone Propionate), Trelegy™ Ellipta® (Fluticasone Furoate/Umeclidinium/Vilanterol), QVAR® RediHaler™ (Beclomethasone Dipropionate), AirDuo™ RespiClick® (Fluticasone Propionate/Salmeterol), and Fasentra™ (Benralizumab) and to Update Nucala® (Mepolizumab) and Xolair® (Omalizumab) Criteria – See Appendix D

A. Introduction

B. Nucala® (Mepolizumab) for Eosinophilic Granulomatosis with Polyangiitis (EGPA)

C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Emflaza® (Deflazacort) – See Appendix E

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Zilretta™ (Triamcinolone Acetonide Extended-Release Injectable Suspension) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Varubi® IV (Rolapitant) and Cinvanti™ (Aprepitant) – See Appendix G

- A. Introduction
- B. Market News
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Action Item – Annual Review of Seizure Medications – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Seizure Medications
- C. Prior Authorization of Seizure Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Seizure Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

11. Annual Review of Osteoporosis Medications and 30-Day Notice to Prior Authorize Tymlos™ (Abaloparatide) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Osteoporosis Medications
- C. Prior Authorization of Osteoporosis Medications
- D. Market News and Updates
- E. Tymlos™ (Abaloparatide) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Osteoporosis Medications

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

12. Annual Review of Antiviral Medications and 30-Day Notice to Prior Authorize Prevymis™ (Letermovir Tablets and Injection) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Antiviral Medications
- C. Prior Authorization of Antiviral Medications
- D. Market News and Updates
- E. Cytomegalovirus Prevention in Hematopoietic Stem Cell Transplant Recipients
- F. Prevymis™ (Letermovir) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Antiviral Medications

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

13. Annual Review of Glaucoma Medications and 30-Day Notice to Prior Authorize Rhopressa® (Netarsudil Ophthalmic Solution) and Vyzulta™ (Latanoprostene Bunod Ophthalmic Solution) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Glaucoma Medications
- C. Prior Authorization of Glaucoma Medications
- D. Market News and Updates
- E. Rhopressa® (Netarsudil Ophthalmic Solution) Product Summary
- F. Vyzulta™ (Latanoprostene Bunod Ophthalmic Solution) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Glaucoma Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

14. Annual Review of Parkinson's Disease (PD) Medications and 30-Day Notice to Prior Authorize Xadago® (Safinamide) and Gocovri™ (Amantadine Extended-Release) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of PD Medications
- C. Prior Authorization of PD Medications
- D. Market News and Updates
- E. Xadago® (Safinamide) Product Summary
- F. Gocovri™ [Amantadine Extended-Release (ER)] Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of PD Medications

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

15. 30-Day Notice to Prior Authorize Mepsevii™ (Vestronidase Alfa-vjbc) – See Appendix M

- A. Introduction
- B. Mepsevii™ (Vestronidase Alfa-vjbc) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

16. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize Ergomar® (Ergotamine Sublingual Tablets) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Migraine Medications
- C. Prior Authorization of Anti-Migraine Medications
- D. Market News and Updates
- E. Ergomar® (Ergotamine Sublingual Tablets) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Migraine Medications

Non-Presentation; Questions Only:

17. Industry News and Updates – See Appendix O

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

- A. Multiple Sclerosis Medications
- B. Spinraza® (Nusinersen)
- C. Luxturna™ (Voretigene Neparvovec-rzyl)
- D. Erythropoiesis Stimulating Agents (ESAs)
- E. Chronic Lymphocytic Leukemia (CLL) Medications

**Future business subject to change.*

20. Adjournment